Marketdash
Back to Stock Market News

BioMarin Snaps Up Amicus in $4.8B Deal That Could Reshape Its Rare Disease Business

MarketDash Editorial Team
2 days ago
BioMarin's acquisition of Amicus Therapeutics brings two billion-dollar assets into the fold, promising immediate earnings accretion and fresh momentum in the competitive rare disease space.

BioMarin Pharmaceutical Inc. (BMRN) announced Friday it's acquiring Amicus Therapeutics, Inc. (FOLD) for roughly $4.8 billion in total equity value, a deal that immediately caught Wall Street's attention for its potential to accelerate growth and diversify revenue.

The acquisition brings two established rare disease therapies into BioMarin's arsenal, and management isn't being shy about the expected benefits. "Immediately upon close, this transaction is expected to accelerate BioMarin's revenue growth and strengthen our financial outlook, delivering significant value to patients, employees, and stockholders. The transaction is expected to be accretive to Non-GAAP Diluted EPS in the first 12 months following close," said Alexander Hardy, President and Chief Executive Officer of BioMarin.

What Analysts Are Saying

Truist Securities maintains BioMarin with a Buy rating and bumped up its price target from $80 to $100, signaling confidence in the combined entity's prospects.

William Blair views the acquisition positively, pointing to the addition of two revenue-generating rare disease therapies that fit naturally with BioMarin's existing capabilities. Analyst Sami Corwin highlighted the strong strategic alignment, noting clear synergies with BioMarin's proven expertise in commercializing rare disease and enzyme therapies.

The deal won't completely shield BioMarin from potential competitive pressure on Voxzogo revenue, but it meaningfully broadens the company's revenue base without taking on clinical development risk. That's a pretty attractive proposition when you're trying to de-risk your growth story.

William Blair acknowledges that Galafold is a more mature asset, which might cap its growth potential. However, the firm believes BioMarin's scale and track record in expanding diagnosis rates and improving patient adherence should help capture the remaining upside in that franchise.

Corwin notes that Pompe disease affects roughly 1 in 18,000 people worldwide. Management believes each acquired asset could generate around $1 billion in peak sales during the 2030s, which would significantly strengthen BioMarin's long-term revenue growth trajectory. The company also expects operational synergies to accelerate growth and boost net profits.

The Technical Picture

BioMarin Pharmaceuticals Inc. is showing bullish momentum in the near term, trading well above its 20-day, 50-day, and 100-day simple moving averages. That's generally a sign of strength, though the story gets more complicated when you zoom out.

The RSI sits at 65.54, landing in neutral territory but edging toward overbought levels. There's upward momentum here, but traders might want to proceed with some caution as the stock approaches that threshold.

The MACD is positioned above its signal line, another bullish indicator suggesting the current trend could have legs. Traders looking for continued upside in the near term have some technical support for that view.

Key levels to watch: support at $52.50 and resistance at $64.00. A bounce off support could signal the uptrend continues, while breaking above resistance might trigger a stronger bullish move.

Here's where things get interesting though. The stock has been wrestling with a longer-term bearish trend, with the 50-day SMA sitting below the 200-day SMA. That relationship tells you that despite the recent strength, the overall longer-term trend remains under pressure.

Over the past 12 months, BMRN is down 8.23%, reflecting some genuine challenges. This decline underscores why it's important to balance short-term optimism with awareness of the broader trend when evaluating the stock's trajectory.

Currently, BMRN is trading at 44.3% of its 52-week range, meaning it's closer to the lower end than the upper. There's room for growth here, but traders should stay alert to potential volatility as the stock attempts to push through resistance levels.

The technical setup suggests cautious optimism is probably the right stance, with the longer-term trend remaining an important consideration.

Price Action: BioMarin Pharmaceutical shares were up 2.45% at $59.37 at the time of publication on Tuesday.

Back to Stock Market News

BioMarin Snaps Up Amicus in $4.8B Deal That Could Reshape Its Rare Disease Business

MarketDash Editorial Team
2 days ago
BioMarin's acquisition of Amicus Therapeutics brings two billion-dollar assets into the fold, promising immediate earnings accretion and fresh momentum in the competitive rare disease space.

BioMarin Pharmaceutical Inc. (BMRN) announced Friday it's acquiring Amicus Therapeutics, Inc. (FOLD) for roughly $4.8 billion in total equity value, a deal that immediately caught Wall Street's attention for its potential to accelerate growth and diversify revenue.

The acquisition brings two established rare disease therapies into BioMarin's arsenal, and management isn't being shy about the expected benefits. "Immediately upon close, this transaction is expected to accelerate BioMarin's revenue growth and strengthen our financial outlook, delivering significant value to patients, employees, and stockholders. The transaction is expected to be accretive to Non-GAAP Diluted EPS in the first 12 months following close," said Alexander Hardy, President and Chief Executive Officer of BioMarin.

What Analysts Are Saying

Truist Securities maintains BioMarin with a Buy rating and bumped up its price target from $80 to $100, signaling confidence in the combined entity's prospects.

William Blair views the acquisition positively, pointing to the addition of two revenue-generating rare disease therapies that fit naturally with BioMarin's existing capabilities. Analyst Sami Corwin highlighted the strong strategic alignment, noting clear synergies with BioMarin's proven expertise in commercializing rare disease and enzyme therapies.

The deal won't completely shield BioMarin from potential competitive pressure on Voxzogo revenue, but it meaningfully broadens the company's revenue base without taking on clinical development risk. That's a pretty attractive proposition when you're trying to de-risk your growth story.

William Blair acknowledges that Galafold is a more mature asset, which might cap its growth potential. However, the firm believes BioMarin's scale and track record in expanding diagnosis rates and improving patient adherence should help capture the remaining upside in that franchise.

Corwin notes that Pompe disease affects roughly 1 in 18,000 people worldwide. Management believes each acquired asset could generate around $1 billion in peak sales during the 2030s, which would significantly strengthen BioMarin's long-term revenue growth trajectory. The company also expects operational synergies to accelerate growth and boost net profits.

The Technical Picture

BioMarin Pharmaceuticals Inc. is showing bullish momentum in the near term, trading well above its 20-day, 50-day, and 100-day simple moving averages. That's generally a sign of strength, though the story gets more complicated when you zoom out.

The RSI sits at 65.54, landing in neutral territory but edging toward overbought levels. There's upward momentum here, but traders might want to proceed with some caution as the stock approaches that threshold.

The MACD is positioned above its signal line, another bullish indicator suggesting the current trend could have legs. Traders looking for continued upside in the near term have some technical support for that view.

Key levels to watch: support at $52.50 and resistance at $64.00. A bounce off support could signal the uptrend continues, while breaking above resistance might trigger a stronger bullish move.

Here's where things get interesting though. The stock has been wrestling with a longer-term bearish trend, with the 50-day SMA sitting below the 200-day SMA. That relationship tells you that despite the recent strength, the overall longer-term trend remains under pressure.

Over the past 12 months, BMRN is down 8.23%, reflecting some genuine challenges. This decline underscores why it's important to balance short-term optimism with awareness of the broader trend when evaluating the stock's trajectory.

Currently, BMRN is trading at 44.3% of its 52-week range, meaning it's closer to the lower end than the upper. There's room for growth here, but traders should stay alert to potential volatility as the stock attempts to push through resistance levels.

The technical setup suggests cautious optimism is probably the right stance, with the longer-term trend remaining an important consideration.

Price Action: BioMarin Pharmaceutical shares were up 2.45% at $59.37 at the time of publication on Tuesday.